LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Strona główna・Stock List・BioNTech SE ADR

BioNTech SE ADR

Closed

SectorHealthcare

92.77 0.5

Buy Sell

Overview

Share price change

24h

Current

Min

91.14

Max

93.03

Key metrics
By Trading Economics
Income	-717M -416M
Sales	-1B 183M
EPS	-1.821
Profit margin	-227.462
Employees	6,772
EBITDA	253M 464M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+51.41% upside

Dividends
By Dow Jones
Next Earnings	4 sie 2025

Market Stats
By TradingEconomics
Market Cap	-1.8B 23B
Previous open	92.27
Previous close	92.77

News Sentiment

By Acuity

43%

57%

150 / 382 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

92.4 / 103.5 Support & Resistance

BioNTech SE ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 lut 2025, 18:52 UTC

Major Market Movers

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

15 lis 2024, 10:28 UTC

Major Market Movers

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

5 maj 2025, 15:13 UTC

Market Talk

Earnings

Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk

15 lis 2024, 11:14 UTC

Market Talk

U.S. Vaccine Stocks Fall After Trump Picks Vaccine Skeptic RFK Jr as Health Department Head-- Market Talk

15 lis 2024, 10:34 UTC

Market Talk

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

5 sie 2024, 10:02 UTC

Earnings

BioNTech Sees 2024 R&D Expenses EUR2.4B-EUR2.6B >BNTX

5 sie 2024, 10:01 UTC

Earnings

BioNTech Backs 2024 View of Rev EUR2.5B-EUR3.1B >BNTX

5 sie 2024, 10:01 UTC

Earnings

BioNTech: Invested EUR525.6M, or About 90% of 2Q R&D Spend, in Non-Covid-19 Related Activities >BNTX

5 sie 2024, 10:00 UTC

Earnings

BioNTech 2Q-End Cash, Equivalents, Security Investments EUR18.5 Billion >BNTX

5 sie 2024, 09:59 UTC

Earnings

BioNTech 2Q Loss EUR807.8M >BNTX

5 sie 2024, 09:59 UTC

Earnings

BioNTech 2Q Loss/Shr EUR3.36 >BNTX

5 sie 2024, 09:59 UTC

Earnings

BioNTech 2Q Rev EUR128.7M >BNTX

Peer Comparison

Price change

BioNTech SE ADR Forecast

Price Target

By TipRanks

51.41% upside

12 Months Forecast

Average 139.81 USD 51.41%

High 171 USD

Low 110 USD

Based on 18 Wall Street analysts offering 12 month price targets forBioNTech SE ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

18 ratings

Buy

Hold

Sell

Based on 18 analysts giving stock ratings to BioNTech SE ADR - Dist in the past 3 months.

Technical Score

By Trading Central

92.4 / 103.5Support & Resistance

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

150 / 382 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac